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Specific involvement of atypical PKCζ/PKMζ in
spinal persistent nociceptive processing following
peripheral inflammation in rat
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Anthony H Dickenson2 and Stephen B McMahon1
Abstract
Background: Central sensitization requires the activation of various intracellular signalling pathways within spinal
dorsal horn neurons, leading to a lowering of activation threshold and enhanced responsiveness of these cells.
Such plasticity contributes to the manifestation of chronic pain states and displays a number of features of long-
term potentiation (LTP), a ubiquitous neuronal mechanism of increased synaptic strength. Here we describe the
role of a novel pathway involving atypical PKCζ/PKMζ in persistent spinal nociceptive processing, previously
implicated in the maintenance of late-phase LTP.
Results: Using both behavioral tests and in vivo electrophysiology in rats, we show that inhibition of this pathway,
via spinal delivery of a myristoylated protein kinase C-ζ pseudo-substrate inhibitor, reduces both pain-related
behaviors and the activity of deep dorsal horn wide dynamic range neurons (WDRs) following formalin
administration. In addition, Complete Freund’s Adjuvant (CFA)-induced mechanical and thermal hypersensitivity
was also reduced by inhibition of PKCζ/PKMζ activity. Importantly, this inhibition did not affect acute pain or
locomotor behavior in normal rats and interestingly, did not inhibited mechanical allodynia and hyperalgesia in
neuropathic rats. Pain-related behaviors in both inflammatory models coincided with increased phosphorylation of
PKCζ/PKMζ in dorsal horn neurons, specifically PKMζ phosphorylation in formalin rats. Finally, inhibition of PKCζ/
PKMζ activity decreased the expression of Fos in response to formalin and CFA in both superficial and deep
laminae of the dorsal horn.
Conclusions: These results suggest that PKCζ, especially PKMζ isoform, is a significant factor involved in spinal
persistent nociceptive processing, specifically, the manifestation of chronic pain states following peripheral
inflammation.
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Background
Peripheral nerve damage or inflammation results in the
induction of molecular mechanisms within the spinal
cord leading to the amplification of the pain signalling
ultimately contributing to persistent pain states [1].
Long term potentiation (LTP) is a ubiquitous mechan-
ism throughout the central nervous system underlying a
long-lasting, localized increase in synaptic strength and
is believed to be the neuronal substrate of learning and
memory [2]. Interestingly, spinal LTP-related phenom-
ena have also been reported in several animal pain mod-
els following either nerve damage or inflammation [3-6].
Furthermore, long-lasting enhancement of pain via high
frequency stimulation in human subjects, considered to
be the perceptual correlate of nociceptive LTP, have
been found [7-9]. As a result, it has recently become
clear that similarities and probably common intracellular
signalling pathways exist between spinal persistent pain
processing and LTP in the hippocampus [4,10].* Correspondence: fabien.marchand@u-clermont1.fr1Neurorestoration Group, Wolfson Centre for Age-related Diseases, King’s
College London, Guy’s Campus, London, SE1 1UL, UK
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PKCζ is an atypical protein kinase belonging to the
protein kinase C (PKC) family, consisting of four func-
tional domains, including regulatory domains and a
kinase domain at the C-terminus [11,12]. In the brain,
not only is the native form of PKCζ (75kDa) expressed,
but also a smaller fragment, PKMζ (51kDa), which con-
sists solely of the independent catalytic domain of PKCζ
and is therefore persistently active. Importantly, PKMζ
is, for instance, the only kinase involved in the mainte-
nance of the late phase of LTP [12-16]. Perhaps more
interestingly, during LTP in the hippocampus, PKMζ is
regulated by several upstream kinases including phos-
phatidylinositol 3-kinase (PI3K), the mammalian target
of Rapamycin (mTOR), Ca2+/calmodulin-dependent
kinase II (CAMKII) and the extracellular signal-regu-
lated kinase (ERK), all of which are also involved in the
establishment of spinal persistent nociceptive sensitiza-
tion including C-fibre-evoked spinal LTP [17-21].
Together with conventional PKC, the activation of PKCζ
could contribute to the morphine-induced rewarding
effect in a neuropathic pain model [22]. Moreover,
along with PKCa and PKCε, PKCζ seems to be involved
in sigma-1 activation induced-facilitation of nociception
[23]. Finally, a very recent study investigated the role of
PKMζ in a spinal sensitized state promoting pain [24].
These authors used a model consisting in an intraplan-
tar injection of IL-6 which induced short term allodynia.
The subsequent intraplantar injection of prostaglandin
E2 or intrathecal injection of a glutamate receptor 1/5
agonist precipitated pain behaviors reflecting a state of
persistent sensitization of the nociceptive pathway.
Spinal inhibition of PKMζ at the time of intraplantar IL-
6 injection or before the subsequent challenge blocked
allodynia and/or nocifensive behaviors demonstrating
the involvement of spinal PKMζ in the initiation and
also the maintenance of a spinal sensitization state.
However, the expression of both PKMζ, PKCζ and their
activated form (i.e. phosphorylated) in the spinal dorsal
horn, the consequence of PKMζ blockade on neuronal
activity in an inflammatory pain context and its role
compared to neuropathic pain have not been yet tested.
Therefore, the aim of this study was to investigate the
involvement of PKCζ/PKMζ in spinal persistent noci-
ceptive processing using models of inflammatory and
neuropathic pain.
Results
Effect of intrathecal administration of ZIP on mechanical
and thermal sensitivity or locomotor function in normal
rats
Intrathecal scrambled peptide (10 μg, n = 8) did not
modify mechanical and thermal withdrawal responses
compared to baseline in normal rats (Figure 1a, b).
More interestingly, intrathecal administration of 10 μg
(n = 8) of ZIP did not alter mechanical and thermal
withdrawal responses compared to baseline and the con-
trol scrambled peptide group throughout the whole
experiment (Figure 1a, b). Finally, neither the control
scrambled peptide nor ZIP had any effect on the loco-
motor function of rats on the rotarod, assessed at 30
and 60 min post-injection (Figure 1c). We subsequently
examined if spinal PKCζ was involved in pain following
peripheral inflammation or nerve injury.
Effect of intrathecal administration of ZIP on pain-related
behaviors induced by intraplantar formalin
In control rats pre-treated spinally with either saline (n
= 8) or the scrambled peptide (10 μg, n = 8), formalin
injection induced a similar biphasic response of pain-
related behaviors, as expected (Figure 1d,e; saline: 1st
phase (0-10 min), = 97 ± 8 s; 2nd phase (10-60 min) =
328 ± 28 s; scrambled peptide: 1st phase = 87 ± 6 s; 2nd
phase = 317 ± 13 s). In contrast, pre-treatment with
ZIP, especially at the highest dose, significantly
decreased pain-related behaviors during both the first
and second phases of the response to formalin (Figure
1d,e; 5 μg: n = 6, 1st phase = 59 ± 9 s, p > 0.05; 2nd
phase = 207 ± 13 s, p < 0.001; 10 μg: n = 9, 1st phase =
46 ± 8 s, p < 0.01; 2nd phase = 145 ± 14 s, p < 0.001)
compared to the scrambled peptide group. As the high
dose (10 μg) of ZIP exhibited a clear antinociceptive
effect in this inflammatory pain model, this dose was
tested in a model of neuropathic pain, the chronic con-
striction injury (CCI).
Effect of intrathecal administration of ZIP on mechanical
allodynia and hyperalgesia in CCI rats
Chronic constriction injury of the sciatic nerve signifi-
cantly decreased mechanical withdrawal responses and
vocalisation thresholds as expected (Figure 1f,g).
Intrathecal scrambled peptide (10 μg, n = 8) did not
modify mechanical withdrawal responses and vocalisa-
tion thresholds compared to baseline post-CCI in CCI
rats (Figure 1f,g). More interestingly, intrathecal admin-
istration of 10 μg (n = 8) of ZIP did not significantly
inhibit mechanical withdrawal responses and vocalisa-
tion thresholds compared to baseline post-CCI and also
the control scrambled peptide group throughout the
whole experiment, indicating a lack of effect of ZIP on
both mechanical allodynia and hyperalgesia following
nerve injury.
Thus, PKCζ/PKMζ seems to be specifically involved in
inflammatory pain and not in acute pain and, interest-
ingly, neuropathic pain. Following these behavioral
results, we have studied the effect of spinal application
of ZIP on deep dorsal horn neurons activity using elec-
trophysiology following formalin administration, and
localisation, expression of PKCζ/PKMζ.
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Figure 1 Spinal blockade of PKCζ/PKMζ activity specifically reduces pain-related behavior induced by intraplantar formalin. Time-
course of (a) mechanical and (b) thermal sensitivity in normal rats following intrathecal administration of the scrambled peptide (10 μg, n = 8)
and PKCζ/PKMζ pseudosubstrate inhibitor, ZIP (10 μg, n = 8). (c) Time spent on the accelerating rotarod (i.e. latency to fall) after intrathecal
injection of the scrambled peptide (10 μg, n = 8) and ZIP (10 μg, n = 8). (d) Time-course of pain-related behaviors following subcutaneous
formalin (5%, 50 μl) injection into the hindpaw following intrathecal pre-treatment with saline (n = 8), the scrambled peptide (10 μg, n = 8) or
ZIP (5 μg or 10 μg, n = 8, *** p < 0.001, ** p < 0.01, * p < 0.05 versus scrambled peptide). (e) Total pain-related behavior during the 1st (0-10
min) and 2nd (10-60 min) phases of the formalin response with saline, scrambled peptide or ZIP (*** p < 0.001, ** p < 0.01, * p < 0.05 versus
scrambled peptide). Time-course of (f) mechanical allodynia and (g) mechanical hyperalgesia in CCI rats following intrathecal administration of
the scrambled peptide (10 μg, n = 8) and ZIP (10 μg, n = 8). All data presented as mean ± s.e.m.
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Effect of spinal application of ZIP on the formalin-induced
firing response of deep dorsal horn WDR neurons
In control rats pre-treated with the scrambled peptide
(10 μg, n = 8), formalin injected into the hindpaw recep-
tive field produced the characteristic biphasic neuronal
firing response of spinal WDR neurons (Figure 2a-c; 1st
phase: 0-10 min, total APs = 8743 ± 1778; 2nd phase:
10-70 min, total APs = 83358 ± 11531). Spinal pre-treat-
ment with ZIP (10 μg, n = 8) reduced both first and sec-
ond phase neuronal firing, though this effect was only
statistically significant on second phase activity (Figure
2a-c; 1st phase: total APs = 4847 ± 979, p > 0.05; 2nd
phase: total APs = 29643 ± 11132, p < 0.001).
Expression and localisation of PKCζ and phospho-PKCζ/p-
PKMζ in the spinal cord
To our knowledge no specific antibody only against
PKMζ is commercially available. Therefore, we used RT-
PCR to identify which mRNA isoforms of PKCζ are
expressed in the DRG and spinal cord of naïve rats. We
found 2 bands at 481 bp and 361 bp as expected for
PKMζ and PKCζ mRNA isoforms, respectively, in our
spinal cord and DRG samples but also in our positive
control samples (i.e. cortex, hippocampus) suggesting
that both mRNA isoforms, and probably proteins, are
expressed in the DRG and spinal cord (Figure 3a).
By western immunoblotting, we investigated the expres-
sion of PKCζ and PKMζ in the DRG, spinal dorsal horn
and hippocampus using a specific anti-PKCζ antibody
(Figure 3b). Western blots analysis confirmed that PKCζ
protein is detected in the hippocampus, DRG and impor-
tantly, spinal dorsal horn (Figure 3b). Using an antibody
against PKCζ/PKMζ active form, i.e. phospho-PKCζ/p-
PKMζ, for which we have characterized the specificity
using the blocking peptide (Figure 4b), we observed that
p-PKCζ/p-PKMζ are expressed in all categories of DRG
neurons, with a highest intensity of immunostaining in the
cytoplasm and membrane of small and medium DRG neu-
rons of naïve rats (Figure 3c). We then investigated if p-
PKCζ/p-PKMζ is transported to and/or expressed in pri-
mary afferent central terminals within the dorsal horn in
formalin animals. Expression of p-PKCζ/p-PKMζ was
Figure 2 Spinal blockade of PKCζ/PKMζ activity reduces the response of deep dorsal horn WDR neurons induced by intraplantar
formalin. (a) Representative rate recordings of firing responses of WDR neurons to formalin following spinal pre-treatment with scrambled
peptide or ZIP. (b) Time-course of WDR firing response to subcutaneous formalin (5%, 50 μl) injection into the hindpaw receptive field following
spinal pre-treatment with scrambled peptide (10 μg, n = 8) or ZIP (10 μg, n = 8, ** p < 0.01 versus scrambled peptide). (c) Total neuronal activity
during the 1st (0-10 min) and 2nd (10-70 min) phases of the formalin response with scrambled peptide or ZIP (2nd phase: *** p < 0.001 versus
scrambled peptide). Results are expressed as mean ± s.e.m.
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observed in the superficial dorsal horn but we did not
observe any obvious co-localisation of p-PKCζ/p-PKMζ
with IB4 and CGRP, specific markers for non-peptidergic
and peptidergic C-fibres, respectively (Figure 3d,e), even at
high power magnification (Figure 4a). In addition, we used
lumbar rhizotomy surgery in a separate experiment to see
if p-PKCζ/p-PKMζ are expressed in primary afferent fibre
terminals as we observed an almost total loss of IB4 and
Figure 3 Expression of PKCζ/PKMζ and phospho-PKCζ/PKMζ. (a) RT-PCR showing expression of PKMζ (481 bp) and PKCζ (361 bp) mRNA
isoforms in spinal cord (spinal c.), dorsal roots ganglia (DRG) and in both cortex and hippocampus (Hippo.) in naïve rats. (b) Western
immunoblot showing expression of PKCζ in hippocampus (Hippo.), DRG and lumbar spinal dorsal horn (Spinal c.) in naïve rats. ß-III tubulin
served as loading control. (c) p-PKCζ/p-PKMζ is co-expressed with IB4 in DRG cells of naïve rats. Scale bars = 50 μm. (d, e) p-PKCζ/p-PKMζ is not
co-expressed with (d) IB4 or (e) CGRP, used as specific markers for non-peptidergic and peptidergic C-fibers, respectively, in spinal cord sections
from formalin rats. Scale bars = 100 μm.
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CGRP staining following rhizotomy, illustrating substantial
deafferentation (Figure 4c,d). Interestingly, we did not
observe any change in spinal p-PKCζ/p-PKMζ staining,
indicating a lack of expression of p-PKCζ/p-PKMζ in pri-
mary afferent fibres terminals (Figure 4c,d) and suggesting
a predominantly intrinsic spinal source.
Consequently, we attempted to identify the phenotype
of p-PKCζ/p-PKMζ-expressing cells in spinal cord sec-
tions from formalin rats (Figure 5a-c). Phospho-PKCζ/p-
PKMζ immunoreactivity was observed in NeuN-positive
cells, marking neuronal nuclei (Figure 5c). No obvious
co-localization was observed with GFAP-positive astro-
cytes or Iba1-positive microglial cells (Figure 5a, b). In
addition, we used immunoprecipitation to reveal a
physical coupling between PKCζ and NR2B subunits,
which are specifically expressed in intrinsic dorsal horn
sensory neurons and are also essential for spinal noci-
ceptive plasticity (Figure 5d). PKCζ protein was co-
immunoprecipitated by the anti-NR2B antibody. Normal
spinal lysate was run alongside immunoprecipitation
samples as positive controls, while CREB and P2X3
were used as two negative control proteins, to verify
that the immunoprecipitation step had worked. The
P2X3 receptor is located exclusively on the central
terminals of primary afferents and CREB is a nuclear
protein, therefore these two proteins should not be
found in a post-synaptic, membrane-associated NR2B/
PKCζ complex (Figure 5d). Indeed, both P2X3 and
Figure 4 Expression of phospho-PKCζ/PKMζ following lumbar rhizotomy. High power magnification of p-PKCζ/p-PKMζ expression with IB4
in spinal cord sections from formalin rats (a). (b) The zeta-specificity of the antibody used is shown using the blocking peptide which drastically
diminished p-PKCζ/p-PKMζ staining (left panel). (c, d) Lumbar rhizotomy caused an almost total loss of (c) IB4 and (d) CGRP staining
demonstrating substantial deafferentation. However, p-PKCζ/p-PKMζ staining still remained. Scale bars = 100 μm.
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CREB were only found in normal spinal tissue lysates,
confirming that non-specific detection of proteins in the
immunoprecipitation sample had not occurred. Thus,
PKCζ is physically coupled to NR2B-containing NMDA
receptors in the spinal dorsal horn.
Together, these results suggest that phosphorylation of
PKCζ/PKMζ following intraplantar formalin is mainly
within intrinsic spinal dorsal horn neurons and could
occurred in NR2B containing NMDA receptors neurons.
However, phosphorylation of PKCζ/PKMζ needed to be
quantified.
Effect of intraplantar formalin on the phosphorylation of
PKCζ/PKMζ expression in the spinal cord
Intraplantar formalin injection in the saline (10 μl, n =
5) and scrambled peptide groups (10 μg, n = 5) pro-
duced a significant increase of p-PKCζ/p-PKMζ in the
superficial (laminae I-II) layers of the ipsilateral dorsal
horn (levels L4-L5) compared to the contralateral side
(mean percentage increase = 27% ± 3.4 and 22% ± 2,
respectively, p < 0.05; Figure 6a,b,d). In addition,
intrathecal injection of ZIP (10 μg, n = 5) did not signif-
icantly alter formalin-induced PKCζ/PKMζ phosphoryla-
tion (mean percentage increase = 25% ± 2; Figure 6c,d).
In addition to immunohistochemistry quantification,
we performed western blot analysis to assess the effect
of intraplatar formalin and also PKCζ/PKMζ inhibition
on the phosphorylation of PKCζ and PKMζ in L4-L5
spinal dorsal horn, 60 min after formalin injection.
Scrambled-treated rats exhibited a significant increase in
p-PKMζ but not p-PKCζ expression compared with the
contralateral dorsal horn (p < 0.05; Figure 6e,f).
Intrathecal administration of ZIP did not alter the phos-
phorylation of PKMζ compared with scrambled-treated
Figure 5 Phospho-PKCζ/PKMζ is expressed in spinal dorsal horn neurons. (a-c) p-PKCζ/p-PKMζ did not co-localize with (a) GFAP or (b) Ib1a
but did co-localize with (c) NeuN. Scale bars = 50 μm. (d) Western immunoblots of naïve rats’ lumbar dorsal horn lysates (left two lanes) and co-
immunoprecipitates from lumbar dorsal horn lysates obtained using an antibody against NR2B (right two lanes), probed with antibodies against
NR2B, PKCζ, CREB and P2X3.
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Figure 6 Effect of spinal PKCζ/PKMζ inhibition on PKCζ/PKMζ phosphorylation in the dorsal horn following intraplantar formalin. (a-c)
Representative photomicrographs of increased expression of p-PKCζ/p-PKMζ in superficial laminae of the ipsilateral lumbar dorsal horn following
intraplantar formalin in rats pre-treated with intrathecal (a) saline, (b) scrambled peptide (10 μg, n = 5) or (c) ZIP (10 μg, n = 5). Scale bars = 100
μm. (d) Quantification of p-PKCζ/p-PKMζ expression in lumbar dorsal horn presented as mean ± s.e.m. of immunofluorescent intensity (arbitrary
unit) of p-PKCζ/p-PKMζ staining in ipsilateral and contralateral lumbar dorsal horn for each group. (e, f) Western immunoblots showing
phosphorylation of PKCζ and PKMζ in formalin rats. Intraplantar injection of formalin induced a significant increase of ipisilateral PKMζ
phosphorylation (e top panel, f) but not PKCζ (e bottom panel, f) compared with the contralateral side in the scrambled peptide treated group.
Intrathecal injection of ZIP (10 μg) did not change the increased phosphorylation of PKMζ (e top panel, f). Results are expressed as mean ± s.e.
m. of the densitometric analysis (arbitrary unit) of p-PKCζ and p-PKMζ expression levels in the ipsilateral and contralateral lumbar dorsal horn for
each group.
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rats (Figure 6e,f). As p-PKCζ expression did not signifi-
cantly increase in the scrambled group following forma-
lin, ZIP was without any effect (Figure 6e,f).
Effect of intraplantar formalin on Fos expression in the
spinal cord
Finally, we evaluated the effect of ZIP on Fos expression
which marks activated neurons. The number of Fos
positive cells in superficial (I-II) and deep (V-VI) lami-
nae of the lumbar dorsal horn (L4, L5 and L6) was
increased at 60 min after intraplantar formalin injection
in scrambled peptide-treated rats (10 μg, n = 5; Figure
7a,c). In contrast, intrathecal pre-treatment with ZIP (10
μg, n = 5) resulted in a significant reduction of Fos-posi-
tive cells in both the superficial (L4: 45.5% ± 5.8 reduc-
tion; L5: 51.3% ± 5.9 reduction; L6: 59.3% ± 1.1
reduction, all p < 0.001) and deep dorsal horn (L4:
53.2% ± 8.4 reduction; L5: 51.6% ± 9.2 reduction; L6:
52.9% ± 11.4 reduction, all p < 0.001) compared to the
scrambled peptide group (Figure 7b,c).
Effect of intrathecal administration of ZIP on mechanical
and thermal hypersensitivity induced by intraplantar CFA
Next, we used a more sustained model of inflammation-
induced spinal nociceptive plasticity, produced by intra-
plantar injection of CFA. Twenty-four hours after CFA
administration, we observed a significant decrease of
mechanical withdrawal thresholds before treatment in
all groups (Figure 8a). Intrathecal scrambled peptide
administration (10 μg, n = 8) did not modify mechanical
withdrawal thresholds, which remained significantly dif-
ferent from baseline throughout the whole experiment.
In contrast, intrathecal administration of 10 μg of ZIP
(n = 8) significantly increased mechanical withdrawal
thresholds 30 min after its administration in comparison
to the scrambled peptide-treated group (increase of 41%
± 14, p < 0.05; Figure 8a). However, mechanical with-
drawal thresholds of the ipsilateral paw still differed sig-
nificantly from that of the contralateral paw (p < 0.05;
Figure 8a). Finally, ZIP had no effect on mechanical
withdrawal thresholds at 90 and 180 min post-injection.
CFA administration also reduced thermal withdrawal
latencies before treatment in all groups (Figure 8b).
Intrathecal scrambled peptide administration did not
alter thermal withdrawal latencies from the baseline
throughout the test period (Figure 8b). In contrast,
intrathecal administration of 10 μg of ZIP significantly
increased thermal withdrawal latencies at 30 and 90 min
post-injection compared to the scrambled peptide group
(30 min: increase of 82.7% ± 31, p < 0.001; 90 min:
increase of 73.5% ± 21, p < 0.05; Figure 8b). Thermal
withdrawal latencies of the ipsilateral paw of ZIP-treated
group still remained significantly different from those of
the contralateral paw at 90 and 180 min.
Effect of intraplantar CFA on the phosphorylation of
PKCζ/PKMζ and Fos expression in the spinal cord
Intraplantar CFA injection in the scrambled peptide
group (10 μg, n = 5) produced a significant increase of
p-PKCζ/p-PKMζ in the superficial (laminae I-II) layers
of the ipsilateral dorsal horn (levels L4-L5) compared to
the contralateral side (mean percentage increase =
19.6% ± 3.3, p < 0.05; Figure 8c,e). As in the formalin
experiment, intrathecal injection of ZIP (10 μg, n = 5)
did not reduce CFA-induced PKCζ/PKMζ phosphoryla-
tion (mean percentage increase = 29.4% ± 6.4; Figure
8d,e).
We also examined the effect of intrathecal administra-
tion of ZIP (10 μg, n = 5) on CFA-induced upregulation
of Fos expression. In CFA animals treated with the
scrambled peptide, we observed a significant increased
expression of Fos in superficial (I-II) and deep (V-VI)
laminae of the ipsilateral lumbar dorsal horn compared
to the contralateral side (Figure 8f,h). In contrast, spinal
delivery of ZIP significantly reduced CFA-induced Fos
expression in superficial (47.2% ± 11.2 reduction) and
deep (46.5% ± 19.4 reduction) laminae of the ipsilateral
lumbar dorsal compared to the control scrambled pep-
tide-treated group (Figure 8g,h).
Discussion
This study demonstrates that atypical PKCζ more speci-
fically the PKMζ isoform is involved in spinal persistent
nociceptive processing only following peripheral inflam-
mation. Indeed, a specific pseudosubstrate inhibitor of
PKCζ/PKMζ, ZIP, injected intrathecally, reduced pain-
related behaviors elicited by intraplantar injection of for-
malin and CFA while it did not modify mechanical and
thermal sensitivity or locomotor function in normal rats
and interestingly, mechanical allodynia and hyperalgesia
in a neuropathic pain model. Furthermore, direct spinal
application of this inhibitor reduced the firing response
of WDR neurons to formalin administration into the
hindpaw receptive field during the second phase. Pain
behaviors in both inflammatory models were associated
with increased expression of the activated form (i.e.
phosphorylated) of PKCζ, especially phospho-PKMζ in
the ipsilateral dorsal horn of formalin rats, suggested to
be specifically within spinal neurons. Finally, inhibition
of PKCζ/PKMζ decreased Fos expression induced by
peripheral inflammation in both superficial and deep
laminae of the lumbar spinal dorsal horn.
Numerous studies have shown increased translocation
and expression of different forms of PKC in dorsal horn
neurons in pain models (for review see [25]). Moreover,
inhibition of PKCs using non-specific PKC inhibitors (e.
g. chelerythrine) reduces inflammation-induced pain
related behaviors [26-28]. PKCε may have a role in neu-
rotransmitter release from primary afferent terminals
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Figure 7 Effect of spinal PKCζ/PKMζ inhibition on Fos expression in the dorsal horn following intraplantar formalin . (a, b)
Representative photomicrographs of formalin-induced upregulation of Fos expression in superficial (I-II) and deep laminae (V-VI) of the ipsilateral
lumbar dorsal horn in rats pre-treated with intrathecal (a) scrambled peptide (10 μg, n = 5) or (b) ZIP (10 μg, n = 5). (c) Quantification of
number of Fos-positive cells in superficial and deep laminae of the lumbar (L4-L6) dorsal horn. All data presented as mean ± s.e.m., * p < 0.05.
Scale bars = 100 μm.
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[29], while PKCg only contributes to increased hyperex-
citability of a subset of lamina V NMDA-dependent
neurons following an inflammatory stimulus, suggesting
only a partial contribution of this kinase in spinal
sensitized state, especially in mediating mechanical
hypersensitivity [30-32]. Therefore, other PKCs must be
involved, with PKMζ a likely contributor since it is
involved in the maintenance of hippocampal LTP
Figure 8 Effect of spinal PKCζ/PKMζ inhibition on pain-related behaviors, PKCζ/PKMζ phosphorylation and Fos expression in spinal
neurons following intraplantar CFA. Time-course of (a) mechanical and (b) thermal hypersensitivity in CFA rats following intrathecal
administration of the scrambled peptide (10 μg, n = 8) or ZIP (10 μg, n = 8). Results are expressed as mean ± s.e.m. (* p < 0.05 versus scrambled
peptide and o p < 0.05 versus the contralateral paw). (c, d) Representative photomicrographs of increased expression of p-PKCζ/p-PKMζ in
superficial laminae of the ipsilateral lumbar dorsal horn following intraplantar CFA in rats pre-treated with intrathecal (c) scrambled peptide (10
μg, n = 5) or (d) ZIP (10 μg, n = 5). (e) Quantification of increased expression of p-PKCζ/p-PKMζ in the ipsilateral dorsal horn presented as a
percentage of contralateral dorsal horn expression. (f, g) Representative photomicrographs of CFA-induced upregulation of Fos expression in
superficial (I-II) and deep laminae (V-VI) of the ipsilateral lumbar dorsal horn in rats pre-treated with intrathecal (f) scrambled peptide (10 μg, n =
5) or (g) ZIP (10 μg, n = 5). (h) Quantification of number of Fos-positive cells in superficial and deep laminae of the lumbar (L4-L6) dorsal horn.
All data presented as mean ± s.e.m. * p < 0.05. Scale bars = 100 μm.
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[13,14]. Thus, we sought to investigate the function of
PKCζ/PKMζ in naïve animals and in both inflammatory
and neuropathic pain models.
Mechanical and thermal nociceptive thresholds as well
as locomotor function in normal rats were unaffected by
spinal PKCζ/PKMζ inhibition by ZIP as also shown for
acute mechanical sensitivity [23,24]. However, pain-
related behaviors in the first and second phases of the
formalin test were significantly reduced following
intrathecal administration of ZIP. This effect observed on
the first phase might suggest that PKCζ/PKMζ is involved
in acute pain but, as demonstrated, ZIP did not affect
nociception in normal rats. The biphasic behavioral
response seen in freely moving animals is mimicked by
the biphasic firing response of WDR neurons to periph-
eral formalin [26,33]. Using this electrophysiological
approach, we observed that the second phase of the for-
malin test considered to underlie spinal nociceptive sen-
sitization was substantially reduced by spinal ZIP
application, indicating an inhibitory effect on neuronal
excitability. In contrast, no significant effects were seen
during the first phase of neuronal response. Monitoring
both the behavioral and neuronal measures, there is a
remarkable concordance, yet the second phase of the for-
malin response was reduced by ZIP but only the first
phase in awake animals. There was a clear but insignifi-
cant reduction in first phase neuronal firing which may
be enough to result in reduced withdrawal responses in
awake animals. We subsequently utilized a more sus-
tained model of inflammatory pain induced by intraplan-
tar CFA, which exhibited significant reduction of their
nociceptive thresholds within 24 hours, indicating the
establishment of spinal persistent nociceptive sensitiza-
tion. Intrathecal administration of ZIP significantly inhib-
ited both mechanical and thermal hypersensitivity. In
contrast to the formalin test, there are few studies on the
effect of spinal PKC inhibition on pain behaviors after
CFA with mixed results [20,34]. Nonetheless, PKCa or
PKCg are apparently involved in the biochemical modifi-
cations of NMDA receptors and/or GluR receptors trans-
location/internalisation within the lumbar spinal cord of
the CFA model [34,35]. Importantly, a very recent study
has shown that spinal PKMζ underlies the initiation but
also the maintenance mechanism of persistent nocicep-
tive sensitization [24]. In a model of “hyperalgesic prim-
ing”, blockage of PKMζ at the time of intraplantar IL-6
inhibited allodynia. PKMζ inhibition before subsequent
challenge with intraplantar PGE2 or intrathecal mGlu1/5
agonist, when IL-6-induced allodynia was completely
resolved, also abolished pain behaviors. Thus, all these
data suggest a specific role of PKCζ/PKMζ in pain and
spinal persistent nociceptive processing, especially fol-
lowing peripheral inflammation. Indeed, intrathecal
administration of ZIP did not modify neuropathy-
induced mechanical hypersensitivity. Moreover, Li et al,
found that spinal ZIP administration did not modify
mechanical allodynia in neuropathic mice, there was no
change in lumbar PKMζ/p-PKMζ expression and ZIP did
not affect neuropathy-induced increased EPSCs from
lamina II neurons [36]. However, they demonstrated a
role of PKMζ in the anterior cingulated cortex in neuro-
pathic pain hypersensitivity [36]. This differential involve-
ment of spinal PKMζ is of crucial importance to
understand the difference of the molecular mechanisms
of persistent spinal nociceptive processing between
inflammatory and neuropathic pain. It is plausible that
the type of stimulus at the periphery and the release of
specific algogenic substances following an inflammatory
stimulus could specifically promote spinal PKMζ activa-
tion. For example, PKCζ has been reported to be involved
in receptor signalling complexes such as TNF-a and IL1-
b receptors and activation of NFkB transcription factor
during immune reactions which can occur in inflamma-
tory pain states. Further studies are definitely needed to
clarify this differential involvement of PKCζ/PKMζ
between inflammatory and neuropathic pain.
Next, we assessed the expression of PKCζ/PKMζ in
naïve animals and whether the phosphorylated forms of
PKCζ/PKMζ change in the ipsilateral lumbar dorsal
horn after peripheral inflammation. In naïve animals,
both mRNA isoforms coding specifically for PKCζ and
PKMζ are present in the DRG and lumbar spinal cord.
Using western immunoblotting, we confirmed expres-
sion of PKCζ protein in the lumbar spinal cord but also
in the DRG and the hippocampus. However, the antid-
ody used specifically recognized PKCζ but not PKMζ.
Nonetheless, we found an expression of phospho-PKCζ/
p-PKMζ mainly in small and medium DRG neurones of
naïve animals. We therefore examined if p-PKCζ/p-
PKMζ are expressed in central terminals of primary
afferent fibres within the spinal cord of formalin rats.
We did not observe any obvious co-staining of p-PKCζ/
p-PKMζ with IB4 and CGRP in lumbar spinal cord. In
addition, using lumbar rhizotomy, which causes a sub-
stantial loss of primary afferent terminals within the
spinal cord [37,38], we still observed p-PKCζ/p-PKMζ
staining in the dorsal horn, suggesting a predominantly
intrinsic spinal source. Indeed, cells expressing p-PKCζ/
p-PKMζ were neuronal as shown by co-expression with
NeuN, a marker of neuronal nuclei and PKCζ is physi-
cally linked to NR2B-containing NMDA receptors using
co-immunoprecipitation. These results suggest that
PKCζ expression is restricted to intrinsic dorsal horn
neurons within superficial laminae and could be an
intracellular protein effector of the NMDA receptor
complex.
We also conducted experiments to examine possible
changes in the levels of phosphorylated (i.e. activated)
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PKCζ and PKMζ in both inflammatory models. We
observed a significant increase of p-PKCζ and p-PKMζ
in the ipsilateral superficial dorsal horn, predominantly
in the medial part, compared to the contralateral side in
both models treated either with saline, the scrambled
peptide or ZIP using immunohistochemistry. Further-
more, we only detected a significant increase of p-PKMζ
but not p-PKCζ expression in the ipsilateral dorsal horn
compared to the contralateral side in formalin rats using
western blot. Finally, ZIP did not affect the phosphoryla-
tion of PKMζ and PKCζ in both models, as previously
demonstrated for PKMζ in hippocampal slices following
electrical stimulation-induced LTP [18]. Therefore, the
antinociceptive effect of this specific enzymatic site inhi-
bitor may be due to a reduction of the phosphorylating
capacity (i.e. catalytic activity) of mainly PKMζ, at least
following formalin, on downstream targets rather than
its ability to be phosphorylated and further activated.
In both inflammatory pain models, we found Fos
upregulation in superficial and deep laminae of the dor-
sal horn, which was reduced by PKCζ/PKMζ inhibition,
reinforcing the hypothesis of a profound effect on neu-
ronal activity. This also suggests that PKCζ/PKMζ is an
upstream regulator of Fos expression. PKCε also influ-
ences Fos expression in the lumbar dorsal horn follow-
ing formalin, though its effects are mediated by
inhibition of neurotransmitter release from primary
afferent fibre terminals [25], while decreased expression
of Fos in PKCg knockout mice following formalin injec-
tion only occurs in laminae I-II [30]. Therefore, other
PKCs, including PKCζ/PKMζ, are certainly involved in
Fos expression and neuronal excitability, particularly in
the deep dorsal horn. The deep dorsal horn neurons
receive nociceptive inputs via interneurons and/or their
dorsally extending dendrites. Thus, as PKCζ/PKMζ is
primarily expressed in superficial dorsal horn, the invol-
vement of this kinase on deep dorsal horn neurons
activity is likely to be indirect. Interestingly, PI3K,
mTOR, CAMKII, and ERK, expressed by dorsal horn
neurons play a crucial role in spinal nociceptive plasti-
city, while also regulating the expression but probably
not the phosphorylation of PKMζ in LTP
[17-19,29,39-41]. Such effectors (e.g. CaMKII, PI3K...)
may influence PKCζ/PKMζ activity, and ultimately con-
tribute to spinal persistent nociceptive processing. We
finally demonstrated a physical link between NR2B-con-
taining NMDA receptors and PKCζ, therefore atypical
PKCζ/PKMζ could participate in NMDA receptors
activity in a context of chronic inflammatory pain but
also through post-synaptic mGlu receptors [24]. Further
studies are needed to investigate the upstream regulators
(e.g. kinases) and downstream targets of spinal PKCζ/
PKMζ in chronic inflammatory pain.
Conclusions
In the present study, we have demonstrated that PKCζ
especially PKMζ isoform may be a significant factor in
spinal persistent nociceptive processing following per-
ipheral inflammation. This role of PKCζ/PKMζ seems to
be restricted to inflammatory pain since there was no
involvement of this kinase in acute and neuropathic
pain. Pharmacological targeting of PKCζ/PKMζ may be
of therapeutic benefit in chronic inflammatory pain
conditions.
Materials and methods
Animals
All experiments were carried out using adult male Wis-
tar rats (220-250g, Harlan, UK or Central Biological Ser-
vices, University College London, UK), housed in
standard laboratory conditions with free access to food
and water. Experiments were approved by the UK
Home Office and followed guidelines set by the Interna-
tional Association for the Study for Pain [42].
Behavioral testing
Experiments were performed in a quiet room by a single
blinded experimenter using the method of equal blocks
with randomization of treatments in order to avoid any
uncontrollable environmental influence that might intro-
duce variability in behavioral responses.
Thermal and mechanical nociception tests in normal rats
Naïve rats (180-200g, Harlan, UK) were injected intrathe-
cally with 10 μg of myristoylated PKCζ pseudosubstrate
inhibitor, ZIP (Myr-SIYRRGARRWRKL-OH; Biosource
International Inc., USA) previously used as a specific inhi-
bitor of PKCζ/PKMζ in several studies [15,24,36,43] or
myristoylated control scrambled peptide (Myr-RLYRK-
RIWRSAGR-OH; Genscript, USA). Thermal and mechani-
cal thresholds were assessed 30, 60, 90 and 120 min post-
injection using the thermal plantar test and automatic
Von Frey test, respectively (for details see below).
Assessment of locomotor function - Rotarod
Locomotor function and motor effects of drugs were
assessed using an accelerating rotarod device (Bioseb,
France). Naïve rats (180-200 g) underwent a training
period over 2 consecutive days (1 trial/day) prior to test-
ing of drug effects in order to ensure that they could
remain on the rotarod at 4 revolutions per minute
(rpm) for 5 min. On the day of drug administration, the
apparatus was set to accelerate from 4 to 40 rpm over 5
min and the latency to fall was monitored. Locomotor
function in the accelerating rotarod was assessed 30 and
60 min following intrathecal injection of ZIP or the
scrambled peptide (both 10 μg/rat).
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Formalin test
Prior to being placed in a Plexiglas box for 30 min to
acclimatize, rats received a direct intrathecal (i.t.) injec-
tion of 5 or 10 μg of myristoylated PKCζ pseudosub-
strate inhibitor, ZIP, (Biosource International Inc., USA),
control scrambled peptide (Genscript, USA) or 0.9% sal-
ine (n = 8 in each group). Thirty minutes later rats
received 50 μl of 5% formalin injected subcutaneously
(s.c.) into the plantar surface of the right hindpaw. Lift-
ing, shaking, biting and licking of the injected paw were
recorded by measuring the total duration of the
response in seconds during the 60 min period following
formalin administration. Data are presented in 5 min
time bins. At the end of the test, animals were termin-
ally anaesthetized and perfused (for details see below).
Induction of mononeuropathy: chronic constriction nerve
injury (CCI)
Unilateral peripheral mononeuropathy was induced
according to the method previously described by [44].
Briefly, rats (150-175 g) were anesthetized with sodium
pentobarbital (6%, 1 ml/kg, i.p.). After skin incision, the
right sciatic nerve was exposed and 4 polyester sutures
(MERSUTURE® 3-0, Ethicon, Johnson & Johnson,
France) were tied loosely around at 1 mm intervals, so
that the nerve was constricted but the circulation was
not interrupted. The skin was then sutured (MONO-
CRYL® 5-0, Ethicon, Johnson & Johnson, Issy-les-Mou-
lineaux, France). The animals were allowed to recover
and were routinely monitored to assure good health. To
examine mechanical allodynia (i.e. Von Frey test) and
hyperalgesia (i.e. paw pressure test), we used two sepa-
rate groups of animals. The right hindpaw was tested
and measurements were taken on two separate days
prior CCI surgery (baseline), 14 days after CCI induction
(baseline post-CCI) and 30, 90 and 180 min or 30, 45,
120, 180 and 240 min for mechanical allodynia and
hyperalgesia, respectively, after administration of a single
direct intrathecal injection of ZIP or the scrambled pep-
tide (both 10 μg/rat, n = 8 in each group).
Induction of peripheral inflammation with CFA
Rats were injected with 50 μl of Complete Freund’s
Adjuvant (CFA; 1mg/ml Mycobacterium Tuberculosis;
Sigma, UK) into the plantar surface of the right hindpaw
to induce inflammation. The CFA-treated paw showed
marked swelling within 2-3 hrs which persisted for sev-
eral days. To examine mechanical and thermal hyper-
sensitivity, the left and right hindpaws were tested
alternatively and measurements were taken on two sepa-
rate days prior to CFA administration, 24 hrs after CFA
injection (baseline post-CFA) and 30, 90 and 180 min
after administration of a single direct intrathecal injec-
tion of ZIP or the scrambled peptide (both 10 μg/rat, n
= 8 in each group). At the end of the experiment, ani-
mals were terminally anaesthetized and perfused (for
details see below).
Thermal and Mechanical hypersensitivity
Each animal was placed in a clear acrylic cubicle (22 ×
16.5 × 14 cm) on top of a glass floor in a temperature
controlled room (~22°C) and allowed to acclimatize for
15 min before testing. Thermal responses were tested
using the method described by [45]. Withdrawal latencies
were averaged over three consecutive tests, at least 5 min
apart, in response to the thermal challenge from a cali-
brated radiant light source (output of 190 mW/cm2). A
cut-off of 20 s was imposed to prevent tissue damage.
Mechanical withdrawal thresholds were tested using a
Dynamic Plantar Aesthesiometer (Ugo Basile, Italy). The
stimulus was applied via an actuator filament (0.5 mm
diameter) which, under computer control, applied a lin-
early increasing force ramp (2.5 g/sec, maximum force
50 g) to the plantar surface of the hindpaw. The force
necessary to elicit paw withdrawal was recorded. The
withdrawal threshold was calculated as the average of
three consecutive tests, with at least 5 min between
each test. A cut-off of 50 g which is the maximum force
applied by the apparatus was used.
In order to assess mechanical hyperalgesia, a group of
CCI rats were submitted to the paw pressure test pre-
viously described by [46]. Nociceptive thresholds,
expressed in grams, were measured using an Ugo Basile
analgesimeter (Bioseb, France) which applied an increas-
ing pressure to the right hind paw until a squeak (voca-
lisation threshold) was elicited. The vocalisation
threshold was measured 2 or 3 times before (baseline)
and after ligatures (baseline post-CCI) in order to obtain
two consecutive values that differed no more than 10%,
and respecting an interval of at least 10 min between
two measures. The maximal pressure (cut-off) applied
was 750 g.
Direct intrathecal injection via lumbar puncture
Intrathecal (i.t.) injections were performed under isoflur-
ane anaesthesia (4% induction, 2% maintenance) accord-
ing to the method previously described [47]. The
anaesthetised rat was held firmly at the pelvic girdle and
drug was delivered (10 μl/rat) using a 25-gauge × 1-inch
needle connected to a 25 μl Hamilton syringe inserted
into the subarachnoidal space between lumbar vertebrae
L5 and L6, eliciting a tail flick. The syringe was held in
position for a few seconds after the injection.
In vivo Electrophysiology - Formalin Test
Preparation
Anaesthesia of rats was induced using 4-5% isoflurane
(66% N2O & 33% O2) and a tracheal cannula was
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inserted, once areflexic. Rats were placed in a stereotaxic
frame to ensure stability during electrophysiological
recordings, and core body temperature was maintained
at 36.5-37°C using a heating blanket connected to a
thermal rectal probe. Anaesthesia was reduced to 2.5%
isoflurane, and a laminectomy was performed at the L1-
L3 vertebral level, exposing the L4-L5 segments of the
spinal cord. Anaesthesia was then reduced to 1.5% iso-
flurane and was maintained at this level for the duration
of the experiment.
Identification of different spinal cell types was
achieved by tapping at the hindpaw receptive field.
Extracellular recordings from single convergent deep
dorsal horn (> 600 μm) wide dynamic range neurons
(WDRs) were made using parylene coated tungsten elec-
trodes (A-M Systems, Washington USA). Cells were
characterised prior to formalin administration. First,
cells were stimulated electrically. A train of 16 transcu-
taneous electrical stimuli (2 ms wide pulses, 0.5 Hz) was
applied at three times the threshold current for C-fibres
via two stimulating needles inserted under the skin of
the hindpaw, in order to assess primary afferent fibre
input. Next, the receptive field was stimulated thermally
by applying a constant jet of water using a needle and
syringe. Both an innocuous (35°C) and noxious (48°C)
temperature was applied in order to indicate a strong C-
fibre input to the WDR neuron being recorded, which
has been shown to be required for the response to sub-
cutaneous formalin [48].
Administration of Drug and Formalin
Following cell characterization, 10 μg of the myristoy-
lated PKCζ pseudosubstrate inhibitor, ZIP (n = 8), in a
total volume of 50 μl, was applied directly onto the sur-
face of the spinal cord using a Hamilton syringe, 30 min
prior to the injection of formalin. A separate group of
control animals (n = 8) received the control scrambled
peptide (10 μg/50 μl).
Formalin (5%, 50 μl) was injected subcutaneously into
the centre of the hindpaw receptive field and the firing
response of the WDR neuron was followed for the sub-
sequent 70 min. Activity was displayed as a rate record-
ing and quantified in 10 min time bins. Data was
captured and analyzed by a CED 1401 interface coupled
to a Pentium computer with Spike 2 software (Cam-
bridge Electronic Design, UK; rate function) and pre-
sented as number of action potentials (APs).
Lumbar rhizotomy surgery
Lumbar rhizotomy was carried out as previously
described by [37] and [38]. In brief, animals were deeply
anaesthetized by intraperitoneal (i.p.) injection of a mix-
ture of medetomidine (0.25 mg/kg) and ketamine (60
mg/kg). Skin and muscle incisions were made to expose
the vertebral laminae. The intervertebral foraminae were
enlarged and L4, L5 and L6 dorsal roots were exposed
and crushed for 10s each. The muscle and skin were
then closed with 4.0 sutures. Seven days after surgery,
animals were deeply anaesthetised and perfused (see
below). Tissue processing (lumbar spinal cord) and
immunostaining were conducted as described below.
Immunohistochemistry for phospho-PKCζ and Fos
At the end of the formalin and CFA behavioral experi-
ments, animals were terminally anaesthetised using pen-
tobarbitone and quickly perfused transcardially with
saline followed by 4% paraformaldehyde (PFA) with 15%
of a saturated solution of picric acid to reduce substan-
tial dephosphorylation. After perfusion, the lumbar
spinal cord was excised, post-fixed for 4 hrs in the per-
fusion fixative, cryoprotected in 20% sucrose in 0.1 M
phosphate buffer (PB) overnight at 4°C, and then frozen
in O.C.T compound. Transverse sections (30 μm) were
cut on a cryostat and thaw-mounted onto glass slides.
Sections were stained for p-PKCζ immunohistochemis-
try as follows: after 3 washes in PBS, sections were incu-
bated for 48 hrs at 4°C with a rabbit primary antibody
for anti-phospho-PKCζ (anti-p-PKCζ, Thr 410 sc-12894-
R; 1:100; Santa Cruz Biotechnology, USA) followed by a
secondary antibody solution for 4 hrs (goat anti-rabbit
IgG-conjugated Alexa Fluor 488™; 1:1000; Molecular
Probes, USA), as previously described [22]. Slides were
washed in PBS and cover-slipped with Vectashield
mounting medium (Vector Laboratories, CA, USA).
Sections were visualized under a Zeiss Axioplan 2
fluorescent microscope running Axiovision 3.1 image
analysis software and classified according to spinal level
(L4, L5 and L6). Quantitative assessment of p-PKCζ/p-
PKMζ staining was carried out by determining the
immunofluorescence intensity using grey scale within a
fixed area of the dorsal horn of the spinal cord (ipsilat-
eral and contralateral to injury), as described by [19]. A
box measuring 104 μm2 (100 × 100) was placed over the
medial part of the superficial dorsal horn and the mean
intensity of each area recorded. The measurement pro-
tocol was carried out on L4-L6 spinal sections of each
animal (at least 5 sections per animal). The background
fluorescence intensity of each tissue section was also
determined and subtracted from recorded values. Data
are presented as mean ± s.e.m. of immunofluorescence
intensity (arbitrary unit) of p-PKCζ/p-PKMζ staining in
ipsilateral and contralateral dorsal horn for each group.
To determine the cellular distribution of p-PKCζ/p-
PKMζ, sections from formalin rats were counterstained
with primary antibodies against markers for neurons
[mouse anti-neuronal nuclei (anti-NeuN); 1:500; Chemi-
con, Hampshire, UK], astrocytes [mouse anti-glial fibril-
lary acidic protein (anti-GFAP); 1:1000; Abcam,
Cambridge, UK], microglial cells [rabbit anti-ionized
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calcium binding adaptor molecule 1 (anti-Iba1); 1:100;
Wako Pure Chemical Industries Ltd, Japan], peptidergic
primary afferent fibres [sheep anti-calcitonin gene
related peptide (anti-CGRP); 1:800; Biomol International
LP, USA], and non-peptidergic primary afferent fibres,
[biotinylated lectin IB4 (anti-IB4); 1:1000; Sigma, UK],
followed by the appropriate secondary antibody solution
[goat anti-rabbit IgG-conjugated Alexa Fluor 546™;
(1:1000; Molecular Probes, USA) for NeuN, GFAP and
Iba1 or anti-sheep Cy3 (1:400; Stratech Scientific Ltd,
UK) and extra avidin-TRICT [1:200; Sigma, UK; for
CGRP and IB4].
Double immunostaining for p-PKCζ/p-PKMζ with
CGRP or IB4 (see protocol above for CGRP or IB4
staining), was also conducted on lumbar spinal cord sec-
tions from a group of animals which had rhizotomy sur-
gery (see 2.5). Following CGRP or IB4 staining, sections
were incubated with rabbit anti-p-PKCζ (Thr 410, sc-
12894-R; 1:100; Santa Cruz Biotechnology, USA) fol-
lowed by secondary antibody solution (goat anti-rabbit
IgG-conjugated Alexa Fluor 488™; 1:1000; Molecular
Probes, USA). Slides were washed in PBS, cover-slipped
and visualised under a Zeiss Axioplan 2 Microscope
(Zeiss, Hertfordshire, UK).
The specificity of p-PKCζ/p-PKMζ immunostaining
was verified by preabsorption of the primary antibody
(Thr 410, sc-12894-R; 1:100; Santa Cruz Biotechnology,
USA) with a 5 times excess (weight/weight) of the pep-
tide used to generate the antibody (sc-12891 P, blocking
peptide) overnight at 4°C. The pre-absorbed peptide was
then centrifuged 20 min at 10 000 rpm and the top half
of the liquid was collected and applied on tissue sec-
tions. A positive control (antibody alone at the same
dilution) and a negative control (lack of primary anti-
body) were run in parallel and applied on sister sections.
The antibody against IB4 was added to all tubes include
in this specificity test. Immunostaining was revealed by
incubation with secondary antibody (goat anti-rabbit
IgG-conjugated Alexa Fluor 546™; 1:1000; Molecular
Probes, USA) for 2 hours.
Sections were processed for Fos staining as follows:
following 3 washes in PBS, sections were incubated
overnight, at room temperature with the primary rabbit
anti-Fos antiserum (1:2500 in PBST-Azide, AB5; Onco-
gene Science, Uniondale, NY, USA). Next, sections were
incubated for 4 hrs with secondary antibody (Alexa-
Fluor™ 488 goat anti-rabbit IgG; 1:1000; Molecular
Probes, USA). Slides were washed in PBS and cover-
slipped with Vectashield mounting medium (Vector
Laboratories, CA, USA). From each animal 4-6 sections
(L4-L6) were randomly selected for counting Fos posi-
tive cells by a blinded investigator and an average of
these counts was taken.
Western immunoblotting and immunoprecipitation
Naïve rats anaesthetized with urethane were sacrificed
by decapitation and fresh dorsal roots ganglia (DRG),
spinal cord (dorsal horn only) and hippocampus were
dissected out and snap frozen. Tissue samples were sub-
sequently homogenized in RIPA (Radioimmunoprecipi-
tation assay) buffer (50 mM Tris HCl pH 7.5, 150 mM
NaCl, 1 mM EDTA, 1% NP-40, 0.1% SDS) + 0.5% DOC
(Deoxycholic acid) + Complete protease inhibitor cock-
tail) using a glass homogenizer. Homogenate was then
centrifuged at 14000 rpm for 10 min at 4°C and super-
natant was collected. DRG, spinal dorsal horn and hip-
pocampus whole cell lysates were next titrated to
determine their protein concentrations using a BCA
Protein Assay kit (Pierce, UK).
In a separate experiment, ipsilateral and contralateral
sides of superficial spinal dorsal horn from scrambled
peptide-treated animals (n = 4) and ZIP-treated animals
(n = 4) were dissected out 60 min after intraplantar for-
malin 5%. Following the dissection, tissues samples fol-
lowed the same procedure as above.
For western immunoblotting, lamaelli loading buffer
was added to DRG, dorsal horn and hippocampus pro-
tein lysates (30 μg) from naïve animals and samples
were incubated at 70°C for 30 min. Samples were then
loaded onto 8% gels and separated by sodium dodecyl
sulphate polyacrylamide gel electrophoresis (SDS-
PAGE). After protein transfer to nitrocellulose mem-
branes, membranes were incubated with rabbit anti-
PKCζ primary antibody (1:500, ab59364, Abcam, UK)
and rabbit anti-neuronal ßIII-tubulin (1:3000, ab18207,
Abcam, UK), which served as a loading control, over-
night at 4°C, in order to identify PKCζ/PKMζ expression
in either DRG, lumbar spinal cord or hippocampus in
naïve rats.
Samples from ipsilateral and contralateral sides of
superficial spinal dorsal horn from formalin rats were
submitted to the same procedure as above and finally
transfer to nitrocellulose membranes. Membranes were
then incubated with rabbit anti-pPKCζ primary antibody
(Thr 410 sc-12894-R; 1:500; Santa Cruz Biotechnology,
USA) overnight at 4°C, in order to quantify p-PKCζ and
p-PKMζ expression between ipsilateral and contralateral
dorsal horn of formalin animals.
Following incubation with dye-linked donkey anti-rab-
bit IR800 or goat anti-mouse IR600 secondary antibody,
proteins were revealed using the Odyssey fluorescence
detection system (Licor, UK). For p-PKCζ and p-PKMζ
expression levels, bands were quantified by densito-
metric analysis using Image J software. Results are
expressed as mean ± s.e.m. of the densitometric analysis
(arbitrary unit) of the phosphorylation of p-PKCζ and p-
PKMζ expression levels in the ipsilateral and
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contralateral dorsal horn for each group (both ipsilateral
and contralateral samples were run on the same gel).
For immunoprecipitation of NR2B subunits, Dyna-
beads® Protein G (Invitrogen Ltd, UK) were washed and
coupled with 5 μg of rabbit anti-NR2B antibody (06-
600, Upstate, USA). Next 500 μg of spinal dorsal horn
lysate from naïve animals was added to the antibody-
dynabeads complex and allowed to incubate overnight
for capture of target antigen. Captured protein was
eluted from the dynabeads by resuspension in 40 μl of
Lamaelli loading buffer and heating at 70°C for 30 min.
Samples were then separated onto 8% gels by SDS-
PAGE. Normal spinal lysates samples were run along-
side IP samples as positive controls. Following electro-
phoresis and protein transfer to nitrocellulose
membranes, membranes were incubated with primary
antibody overnight at 4°C. Antibodies used were mouse
anti-NR2B (1:500, 75-101, Neuromab, USA), rabbit anti-
PKCζ (1:500, ab59364, Abcam, UK). Membranes were
also probed with rabbit anti-CREB (1:500, ab5803,
Abcam, UK) and rabbit anti-P2X3 (1:500, ab10269,
Abcam, UK) antibodies used as negative controls. Fol-
lowing incubation with dye-linked donkey anti-rabbit
IR800 or goat anti-mouse IR600 secondary antibody,
proteins were revealed using the Odyssey fluorescence
detection system (Licor, UK).
RT-PCR
Total RNA from cortex, hippocampus, spinal cord and
DRG from naïve rats was used to synthesize cDNA with
the SuperScript™ II Reverserve Transcriptase kit (Invi-
trogen). 1 μg of cDNA was used for PCR (50 μl final
reaction volume) and amplified according to [11]. Cycle
parameters were set as 34 cycles at 94°C for 30 s, 60°C
for 1 min and 72°C for 1 min, with a final step of 72°C
for 10 min. For amplification, F 5’-CCATGCCCAG-
CAGGACCACC-3’ and 5’-CCTTCTATTA-
GATGCCTGCTCTCC-3’ were used as specific forward
primers for PKCζ and PKMζ, respectively and R 5’-
TGAAGGAAGGTCTACACCATCGTTC-3’ was the
reverse primer for both.
Statistical analysis
All data are presented as mean ± s.e.m. Cell characteris-
tics from PKCζ/PKMζ pseudosubstrate inhibitor or
scrambled peptide groups were compared by one-way
analysis of variance (ANOVA), followed by Bonferroni’s
post-test. Formalin neuronal and behavioral response
time-course data for formalin and CFA rats were com-
pared between treatment groups by two-way repeated
measures (RM) ANOVA, followed by Bonferroni’s post-
test. Total activity in the first and second phases was
compared between treatment groups by one-way
ANOVA, followed by Bonferroni’s post-test.
Immunostaining and western immunoblotting of p-
PKCζ/p-PKMζ and Fos was analyzed by one-way and
two-way ANOVA, respectively, followed by Bonferroni
post-tests. Statistical analyses were carried out using
GraphPad Prism v.4 software (GraphPad Software Inc.,
San Diego, CA, USA).
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